Novavax (NVAX) - Vaccine Testing - SARS, MERS, SARS-CoV-2 (2019)

롱

Novavax, Inc. (NASDAQ:NVAX)

업데이트됨

NASDAQ:NVAX Novavax, Inc.

trendanalysis chartpattern fundamental coronavirus coronaviruses history historyrepeatsitself vaccine healthcare biotech biopharma

This is an interesting idea based on outbreaks of SARS, MERS, and SARS-CoV-2 (2019).

Novavax successfully created vaccines for SARS, MERS, and are on track to create one for SARS-CoV-2 (2019) -

Vaccine in development for SARS-CoV-2 (2019):

Is this a good investment? If the vaccination is successful and/or coronavirus outbreak continues, it could trend upwards significantly.

Disclaimer: This is not financial advice. Just my own opinion based on research.

Important Notes: For your own safety, the CDC recommends you WASH YOUR HANDS FREQUENTLY. COVER YOUR MOUTHS WHEN YOU COUGH/SNEEZE.

코멘트:

NanoFlu Vaccine: Phase 3 top-line data due 1Q 2020.
Source:

코멘트:

Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
- Trial also achieves statistical significance in key secondary endpoints
- Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway
- Company to host investor conference call today at 8:30 a.m. EDT

코멘트:

Just to add:
1 reverse-split in its history according to this website ()

코멘트:

Just a note here. COVID in my humble opinion is just a short-term pump for this company. Their real success lies in their NanoFlu technology that can grab a handful of influenza vaccine market.

코멘트:

During earnings announcement, Novavax reported a loss of $0.58/share versus $2.11 last year. They also announced funding of $384 mil from the Coalition for Epidemic Preparedness Innovations. There is a huge spotlight on them now.

Source:

코멘트:

NVAX +15% this morning. Analysts are finally rethinking the potential of Novavax and their technology.

코멘트:

To re-iterate from my previous post on May 6th:

I'm bull-ish on Novavax (see Related Idea). I think their approach to the COVID-19 vaccine is promising - their recombinant nanoparticle vaccine technology and Matrix-M adjuvant. They also have positive long-term prospects with their proprietary NanoFlu candidate. This is the big one to me. It's unclear whether COVID-19 becomes seasonal or not but influenza is established and recurring. It fact, it's becoming more difficult to handle with every year. The strains are becoming more advanced and unpredictable. Whether or not Novavax can produce a profitable candidate, I simply don't know. I believe that their patented tech is promising.

Novavax might not produce a COVID vaccine before its competitors (or at all) but they continue to demonstrate their technology and approach works. Example:

That being said, tell me about this random Schiff I plotted :)

Matrix-M Adjuvant:
NanoFlu Phase 3 topline data:
RSV F Vaccine:

코멘트:

Preliminary studies on COVID vaccines have produced promising results

[NVAX] Novavax: Preliminary studies produce promising results

코멘트:

Novavax almost 100x since Feb 2020. I'm waiting for news of NanoFlu. I still think Novavax has a lot more potential to grow if NanoFlu proves to be superior to all other vaccines in its latest clinical trial.